<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156975</url>
  </required_header>
  <id_info>
    <org_study_id>ADHOC</org_study_id>
    <nct_id>NCT00156975</nct_id>
  </id_info>
  <brief_title>Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases</brief_title>
  <official_title>Adjuvant Chemotherapy With Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases- Randomized Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgruppe Lebermetastasen und Tumoren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbeitsgruppe Lebermetastasen und Tumoren</source>
  <brief_summary>
    <textblock>
      Primary endpoint of the study is to prove the superiority of an adjuvant therapy with
      oxaliplatin/ capecitabine until the first occurrence of appearance of a tumour. Occurrences
      in the meaning of this study are the appearance of a relapse of the tumour, of metastases, of
      a second tumour or death of any reason.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, multi-centre, open phase III study with two parallel groups of
      patients according to the eligibility criteria. The times in both hierarchical classified
      endpoints will be measured as times from randomization.

      Patients with macroscopic complete resection of colorectal liver metastases will be
      randomized in:

      Arm A: post-operative adjuvant therapy with Capecitabine/ Oxaliplatin over 6 months and
      follow-up

      or

      Arm B: follow-up

      Randomization: stratification after Scores of Fong et al:

        -  number of metastases (1 vs. &gt;=1)

        -  maximal diameter of the metastasis (&lt;= 5cm vs. &gt; 5cm)

        -  disease free interval (&gt;= 12 months vs. &gt; 12 months)

        -  CEA (&lt;= 200ng/l vs. &gt;200 ng/l) in the strata 0-1, 2 and &gt;= 3,
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcomes:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes:overall survival,acute- and longtime toxicity of chemotherapy, molecular predictive markers for the risk of relapse and toxicity</measure>
  </secondary_outcome>
  <enrollment>384</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Liver Metastases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients after R0-resection of colorectal liver metastases

          -  age: &gt;= 18 years

          -  Karnofsky-Index &gt;= 70%

          -  neutrophiles &gt;1,5 x10e9/l, thrombocytes 100 x10e9/l

          -  adequate contraception for male and female patients

          -  oral and written informed consent (GCP)

        Exclusion Criteria:

          -  other prior malignancies, except treated in situ-carcinoma of cervix or tumours of
             skin without indication to a melanoma (or 10 years tumourfree)

          -  other participation in clinical trials within 30 days before randomization

          -  previous chemotherapy (except adjuvant chemotherapy with an interval of &gt;= 6 months)

          -  creatinine clearance &lt;50 ml/min

          -  hepatic insufficiency (ALAT, ASAT, Bilirubin, AP &gt;5 x upper limit)

          -  peripheral neuropathy &gt; CTC grade 1

          -  uncontrolled cardiac insufficiency or angina pectoris

          -  active infections

          -  severe neurological or psychiatric illness

          -  breast-feeding or pregnant women

          -  incapacity to take part in regular visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolf O. Bechstein, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arbeitsgruppe Lebermetastasen und Tumoren</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus, Medizinische Klinik</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>011307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen, Klinik für Allgemein- und Transplantationschirurgie OPZ II</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Allgemein- und Gefäßchirurgie , J. W. Goethe Universität</name>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>December 24, 2009</last_update_submitted>
  <last_update_submitted_qc>December 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2009</last_update_posted>
  <keyword>Oxaliplatin</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Resection</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Liver resection</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

